The Role of the Renin-Angiotensin-Aldosterone System in Obesity-Related Renal Diseases

Seminars in Nephrology

Volumn 33, Issue 1, 2013, Pages 44-53

  Rüster, Christiane ^a   Wolf, Gunter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Angiotensin II; Glomerulosclerosis; Metabolic syndrome; Obesity

Indexed keywords

ALBUMIN; ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRBESARTAN; LIPID; LISINOPRIL; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; RENIN; ROSUVASTATIN; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADIPOSE TISSUE; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; KIDNEY DISEASES; METABOLIC SYNDROME X; OBESITY; RENIN-ANGIOTENSIN SYSTEM;

EID: 84873106976     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.12.002     Document Type: Article

References (121)

1. Finucane M.M., Stevens G.A., Cowan M.J., Danaei G., Lin J.K., Paciorek C.J., et al. Global burden of metabolic risk factors of chronic diseases collaborating group (body mass index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377:557-567.
2. Obesity and overweight. Fact sheet no. 311. Updated March 2011 World Health Organization, [cited 2012 August 1]. http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
3. Global Health Risks: mortality and burden of disease attributable to selected major risks 2009. [cited 2012 August 1] World Health Organization. http://www.who.int/healthinfo/global_burden_disease/global_health_risks/en/index.html.
4. Hsu C.Y., McCulloch C.E., Iribarren C., Darbinian J., Go A.S. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006, 144:21-28.
5. Tanner R.M., Brown T.M., Muntner P. Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Curr Hypertens Rep 2012, 14:152-159.
6. Thomas G., Sehgal A.R., Kashyap S.R., Srinivas T.R., Kirwan J.P., Navaneethan S.D. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011, 6:2364-2373.
7. Tang J., Yan H., Zhuang S. Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol. [2012 April 5]. 2012;2012:608397 http://www.hindawi.com/journals/ijn/.
8. Chen H.M., Li S.J., Chen H.P., Wang Q.W., Li L.S., Liu Z.H. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 2008, 52:58-65.
9. Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant 2005, 20:2594-2597.
10. Chagnac A., Weinstein T., Herman M., Hirsh J., Gafter U., Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003, 14:1480-1486.
11. Shen W.W., Chen H.M., Chen H., Xu F., Li L.S., Liu Z.H. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol 2010, 5:1401-1409.
12. Thethi T., Kamiyama M., Kobori H. The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep 2012, 14:160-169.
13. Engeli S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contrib Nephrol 2006, 151:122-134.
14. Wolf G., Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799-812.
15. Rüster C., Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol 2011, 22:1189-1199.
16. Ferrario C.M., Ahmad S., Joyner J., Varagic J. Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). Adv Pharmacol 2010, 59:197-233.
17. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003, 100:8258-8263.
18. Ferrario C.M. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension 2010, 55:445-452.
19. Slee A.D. Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab (Lond) 2012, 9:36.
20. Cassis L.A., Police S.B., Yiannikouris F., Thatcher S.E. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep 2008, 10:93-98.
21. Massiera F., Seydoux J., Geloen A., Quignard-Boulange A., Turban S., Saint-Marc P., et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001, 142:5220-5225.
22. Massiéra F., Bloch-Faure M., Ceiler D., Murakami K., Fukamizu A., Gasc J.M., et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001, 15:2727-2729.
23. Van Harmelen V., Ariapart P., Hoffstedt J., Lundkvist I., Bringman S., Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res 2000, 8:337-341.
24. Yasue S., Masuzaki H., Okada S., Ishii T., Kozuka C., Tanaka T., et al. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens 2010, 23:425-431.
25. Yvan-Charvet L., Even P., Bloch-Faure M., Guerre-Millo M., Moustaid-Moussa N., Ferre P., et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005, 54:991-999.
26. Kouyama R., Suganami T., Nishida J., Tanaka M., Toyoda T., Kiso M., et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005, 146:3481-3489.
27. Sampaio W.O., Santos R.A.S., Faria-Silva R., Mata Machado L.T., Schiffrin E.L., Touyz R.M. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007, 49:185-192.
28. Santos S.H., Fernandes L.R., Mario E.G., Ferreira A.V., PÔrto L.C., Alvarez-Leite J.I., et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008, 57:340-347.
29. Oh Y.B., Kim J.H., Park B.M., Park B.H., Kim S.H. Captopril intake decreases body weight gain via angiotensin-(1-7). Peptides 2012, 37:79-85.
30. Hall J.E., Henegar J.R., Dwyer T.M., Liu J., Da Silva A.A., Kuo J.J., et al. Is obesity a major cause of chronic kidney disease?. Adv Ren Replace Ther 2004, 11:41-54.
31. Saiki A., Ohira M., Endo K., Koide N., Oyama T., Murano T., et al. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism 2009, 58:708-713.
32. Engeli S., Böhnke J., Gorzelniak K., Janke J., Schling P., Bader M., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356-362.
33. O'Seaghdha C.M., Hwang S.J., Vasan R.S., Larson M.G., Hoffmann U., Wang T.J., et al. Correlation of renin angiotensin and aldosterone system activity with subcutaneous and visceral adiposity: the Framingham Heart Study. BMC Endocr Disord 2012, 12:3. 4.
34. Bochud M., Nussberger J., Bovet P., Maillard M.R., Elston R.C., Paccaud F., et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006, 48:239-245.
35. Nagase M., Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 2008, 12:233-242.
36. de Paula R.B., da Silva A.A., Hall J.E. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41-47.
37. Bomback A.S., Klemmer P.J. Renal injury in extreme obesity: the important role of aldosterone. Kidney Int 2008, 74:1216. author reply, 1216-7.
38. Briones A.M., Cat A.N., Callera G.E., Yogi A., Burger D., He Y., et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012, 59:1069-1078.
39. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension 2010, 55:813-818.
40. Ehrhart-Bornstein M., Arakelyan K., Krug A.W., Scherbaum W.A., Bornstein S.R. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 2004, 30:865-870.
41. Nagase M., Yoshida S., Shibata S., Nagase T., Gotoda T., Ando K., et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006, 17:3438-3446.
42. Leopold J.A., Dam A., Maron B.A., Scribner A.W., Liao R., Handy D.E., et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007, 13:189-197.
43. Hirata A., Maeda N., Hiuge A., Hibuse T., Fujita K., Okada T., et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009, 84:164-172.
44. Guo C., Ricchiuti V., Lian B.Q., Yao T.M., Coutinho P., Romero J.R., et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008, 117:2253-2261.
45. Chagnac A., Weinstein T., Korzets A., Ramadan E., Hirsch J., Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000, 278:817-822.
46. Henegar J.R., Bigler S.A., Henegar L.K., Tyagi S.C., Hall J.E. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001, 12:1211-1217.
47. Ahmed S.B., Fisher N.D., Stevanovic R., Hollenberg N.K. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension 2005, 46:1316-1320.
48. Zhuo J.L., Li X.C. New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. Peptides 2011, 32:1551-1565.
49. Chung S., Park C.W., Shin S.J., Lim J.H., Chung H.W., Youn D.Y., et al. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. Nephrol Dial Transplant 2010, 25:389-399.
50. Kim S., Soltani-Bejnood M., Quignard-Boulange A., Massiera F., Teboul M., Ailhaud G., et al. The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system. J Biomed Biotechnol 2006, 2006:27012.
51. Kawarazaki W., Nagase M., Yoshida S., Takeuchi M., Ishizawa K., Ayuzawa N., et al. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol 2012, 23:997-1007.
52. Hirono Y., Yoshimoto T., Suzuki N., Sugiyama T., Sakurada M., Takai S., et al. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology 2007, 148:1688-1696.
53. Kawarazaki H., Ando K., Fujita M., Matsui H., Nagae A., Muraoka K., et al. Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats. Am J Physiol Renal Physiol 2011, 300:1402-1409.
54. Whaley-Connell A., Habibi J., Wei Y., Gutweiler A., Jellison J., Wiedmeyer C.E., et al. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2009, 296:1013-1022.
55. Zhu A., Yoneda T., Demura M., Karashima S., Usukura M., Yamagishi M., et al. Effect of mineralocorticoid receptor blockade on the renal renin-angiotensin system in Dahl salt-sensitive hypertensive rats. J Hypertens 2009, 27:800-805.
56. Lea W.B., Kwak E.S., Luther J.M., Fowler S.M., Wang Z., Ma J., et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009, 75:936-944.
57. Luther J.M., Luo P., Wang Z., Cohen S.E., Kim H.S., Fogo A.B., et al. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int 2012, 37:79-85.
58. Kagami S. Involvement of glomerular renin-angiotensin system (RAS) activation in the development and progression of glomerular injury. Clin Exp Nephrol 2012, 16:214-220.
59. Huang Y., Wongamorntham S., Kasting J., McQuillan D., Owens R.T., Yu L., et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006, 69:105-113.
60. Sakoda M., Ichihara A., Kurauchi-Mito A., Narita T., Kinouchi K., Murohashi-Bokuda K. Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Am J Hypertens 2010, 23:575-580.
61. Reudelhuber T.L. The interaction between prorenin, renin and the (pro)renin receptor: time to rethink the role in hypertension. Curr Opin Nephrol Hypertens 2012, 21:137-141.
62. Ye M., Wysocki J., William J., Soler M.J., Cokic I., Batlle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006, 17:3067-3075.
63. Wong D.W., Oudit G.Y., Reich H., Kassiri Z., Zhou J., Liu Q.C., et al. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 2007, 171:438-451.
64. Kagami S. Involvement of glomerular renin-angiotensin system (RAS) activation in the development and progression of glomerular injury. Clin Exp Nephrol 2012, 16:214-220.
65. Lardizabal J.A., Deedwania P.C. The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus. Curr Cardiol Rep 2010, 12:464-471.
66. Luther J.M., Brown N.J. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci 2011, 32:734-739.
67. Griendling K.K., Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signalling. Regul Pept 2000, 91:21-27.
68. Diamond-Stanic M.K., Henriksen E.J. Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism. Arch Physiol Biochem 2010, 116:88-95.
69. McCarty M.F. ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes. Med Hypotheses 2003, 60:779-783.
70. Yavuz D., Koç M., Toprak A., Akpinar I., Velioǧlu A., Deyneli O., et al. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst 2003, 4:197-203.
71. Marzetti E., Calvani R., Dupree J., Lees H.A., Giovannini S., Seo D.O., et al. Late-life enalapril administration induces nitric oxide-dependent and independent metabolic adaptations in the rat skeletal muscle. Age (Dordr) 2012 May 26, 10.1007/s11357-012-9428-4. Epub ahead of print.
72. Lteif A.A., Chisholm R.L., Gilbert K., Considine R.V., Mather K.J. Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension. Diabetes Obes Metab 2012, 14:254-261.
73. Csibi A., Communi D., Müller N., Bottari S.P. Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms. PLoS One 2010, 5:10070.
74. Muñoz M.C., Giani J.F., Dominici F.P., Turyn D., Toblli J.E. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens 2009, 27:2409-2420.
75. Rodriguez R., Viscarra J.A., Minas J.N., Nakano D., Nishiyama A., Ortiz R.M. Angiotensin receptor blockade increases pancreatic insulin secretion and decreases glucose intolerance during glucose supplementation in a model of metabolic syndrome. Endocrinology 2012, 153:1684-1695.
76. Rong X., Li Y., Ebihara K., Zhao M., Naowaboot J., Kusakabe T., et al. Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia 2010, 53:1727-1731.
77. Sowers J.R., Whaley-Connell A., Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776-783.
78. Kumagai E., Adachi H., Jacobs D.R., Hirai Y., Enomoto M., Fukami A., et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension 2011, 58:1043-1048.
79. Hannemann A., Meisinger C., Bidlingmaier M., Döring A., Thorand B., Heier M., et al. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol 2011, 164:751-758.
80. Giacchetti G., Ronconi V., Turchi F., Agostinelli L., Mantero F., Rilli S., et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007, 25:177-186.
81. Catena C., Lapenna R., Baroselli S., Nadalini E., Colussi G., Novello M., et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006, 91:3457-3463.
82. Urbanet R., Pilon C., Calcagno A., Peschechera A., Hubert E.L., Giacchetti G., et al. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J Clin Endocrinol Metab 2010, 95:4037-4042.
83. Lastra G., Whaley-Connell A., Manrique C., Habibi J., Gutweiler A.A., Appesh L., et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008, 295:110-116.
84. Sherajee S.J., Fujita Y., Rafiq K., Nakano D., Mori H., Masaki T., et al. Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arterioscler Thromb Vasc Biol 2012, 32:257-263.
85. Muñoz M.C., Giani J.F., Burghi V., Mayer M.A., Carranza A., Taira C.A., et al. The Mas receptor mediates modulation of insulin signaling by angiotensin-(1-7). Regul Pept 2012, 177:1-11.
86. Shiuchi T., Iwai M., Li H.S., Wu L., Min L.J., Li J.M., et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004, 43:1003-1010.
87. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
88. McMurray J.J., Holman R.R., Haffner S.M., Bethel M.A., Holzhauer B., et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1477-1490. NAVIGATOR Study Group.
89. Yuan L., Li X., Li J., Li H.L., Cheng S.S. Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet. Acta Diabetol 2010 Jul 14, 10.1007/s00592-010-0210-8. Epub ahead of print.
90. Cole B.K., Keller S.R., Wu R., Carter J.D., Nadler J.L., Nunemaker C.S. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010, 55:715-721.
91. Iwai M., Kanno H., Tomono Y., Inaba S., Senba I., Furuno M., et al. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens 2010, 28:1471-1481.
92. van der Zijl N.J., Moors C.C., Goossens G.H., Hermans M.M., Blaak E.E., Diamant M. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care 2011, 34:845-851.
93. Gyebi L., Soltani Z., Reisin E. Lipid nephrotoxicity: new concept for an old disease. Curr Hypertens Rep 2012, 14:177-181.
94. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260-269.
95. Ran J., Hirano T., Adachi M. Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab 2004, 287:955-961.
96. Kouyama R., Suganami T., Nishida J., Tanaka M., Toyoda T., Kiso M., et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005, 146:3481-3489.
97. Mori Y., Itoh Y., Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 2007, 24:146-153.
98. Kamari Y., Harari A., Shaish A., Peleg E., Sharabi Y., Harats D., et al. Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats. Hypertens Res 2008, 31:135-140.
99. Younis F., Stern N., Limor R., Oron Y., Zangen S., Rosenthal T. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation. Metabolism 2010, 59:1200-1209.
100. Sugimoto K., Kazdová L., Qi N.R., Hyakukoku M., Kren V., Simáková M., et al. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. J Hypertens 2008, 26:1209-1215.
101. Dominguez J.H., Tang N., Xu W., Evan A.P., Siakotos A.N., Agarwal R., et al. Studies of renal injury III: lipid-induced nephropathy in type II diabetes. Kidney Int 2000, 57:92-104.
102. Streather C.P., Varghese Z., Moorhead J.F., Scoble J.E. Lipiduria in renal disease. Am J Hypertens 1993, 6:353-357.
103. Temm C., Dominguez J.H. Microcirculation: nexus of comorbidities in diabetes. Am J Physiol Renal Physiol 2007, 293:486-493.
104. Dominguez J., Wu P., Packer C.S., Temm C., Kelly K.J. Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy. Am J Physiol Renal Physiol 2007, 293:670-679.
105. Kelly K.J., Wu P., Patterson C.E., Temm C., Dominguez J.H. LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes. Am J Physiol Renal Physiol 2008, 294:1136-1145.
106. Liu Y., Wang Z.B., Yin W.D., Li Q.K., Cai M.B., Yu J., et al. Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs. Lipids Health Dis 2011, 10:117.
107. Mason J.C. The statins-therapeutic diversity in renal disease?. Curr Opin Nephrol Hypertens 2005, 14:17-24.
108. Zoja C., Corna D., Gagliardini E., Conti S., Arnaboldi L., Benigni A., et al. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol 2010, 299:1203-1211.
109. Cattaneo D., Remuzzi G. Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. J Ren Nutr 2005, 15:71-76.
110. Saito K., Ishizaka N., Hara M., Matsuzaki G., Sata M., Mori I., et al. Lipid accumulation and transforming growth factor-beta upregulation in the kidneys of rats administered angiotensin II. Hypertension 2005, 46:1180-1185.
111. Garrison R.J., Kannel W.B., Stokes J., Castelli W.P. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987, 16:235-251.
112. Ruggenenti P., Fassi A., Ilieva A.P., Bruno S., Iliev I.P., Brusegan V., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
113. Haller H., Ito S., Izzo J.L., Januszewicz A., Katayama S., Menne J., et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011, 364:907-917.
114. Parving H.H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
115. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
116. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
117. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446. AVOID Study Investigators.
118. Imai E., Chan J.C., Ito S., Yamasaki T., Kobayashi F., Haneda M., et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011, 54:2978-2986.
119. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
120. Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D., Haffner S.M., Solomon S.D., et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst [cited 2012 February 14]. 10.1177/1470320311434818. http://jra.sagepub.com.
121. Angeli F., Reboldi G., Mazzotta G., Poltronieri C., Garofoli M., Ramundo E., et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf 2012, 7:76-85.